Mouse APOE Christchurch protects against Aβ-induced tau and α-synuclein aggregation
Year: 2026
Type: article
Abstract: Apolipoprotein E ( APOE ) genotype alters the risk for Alzheimer's disease (AD) but also affects dementia risk in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Recent evidence suggests that the APOE Christchurch (CC) mutation protects against AD, however, its effects on PD and DLB are unknown. We generated an APOE CC knock-in mouse to understand its effects on amyloid-β (Aβ), tau, and α-synuclein (α-syn) aggregation. APOE CC mice show increased plasma cholesterol and triglyceride levels, decreased Aβ and Aβ-induced tau pathology after intracortical AD-tau injection into 5xFAD mice but do not change Aβ or tau pathology in individual transgenic mouse models without injection. Interestingly, APOE CC reduces formation and spread of α-syn aggregation in the brain, peripheral-to-spinal cord spread, and directly increases binding affinity to α-syn compared to APOE WT. Our study emphasizes the remarkable protective effects of a point mutation in murine APOE against Aβ-induced tau and α-syn aggregation.
Source: Cell Reports
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,620
OpenAlex ID: W4415999295
